80 related articles for article (PubMed ID: 16172791)
1. Celecoxib inhibits urokinase-type plasminogen activator (uPA) production in MDA-MB-231 breast cancer cells.
Andrews HN; Habibi G; Kucab JE; Dunn SE
Breast Cancer Res Treat; 2005 Nov; 94(1):47-52. PubMed ID: 16172791
[TBL] [Abstract][Full Text] [Related]
2. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
[TBL] [Abstract][Full Text] [Related]
3. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
[TBL] [Abstract][Full Text] [Related]
4. In vitro suppression of urokinase plasminogen activator in breast cancer cells--a comparison of two antisense strategies.
Arens N; Gandhari M; Bleyl U; Hildenbrand R
Int J Oncol; 2005 Jan; 26(1):113-9. PubMed ID: 15586231
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of human breast cancer cell (MBA-MD-231) invasion by the Ea4-peptide of rainbow trout pro-IGF-I.
Siri S; Chen MJ; Chen TT
J Cell Biochem; 2006 Dec; 99(5):1363-73. PubMed ID: 16795042
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells.
Basu GD; Pathangey LB; Tinder TL; Gendler SJ; Mukherjee P
Breast Cancer Res; 2005; 7(4):R422-35. PubMed ID: 15987447
[TBL] [Abstract][Full Text] [Related]
7. Urokinase-type plasminogen activator induces proliferation in breast cancer cells.
Gandhari M; Arens N; Majety M; Dorn-Beineke A; Hildenbrand R
Int J Oncol; 2006 Jun; 28(6):1463-70. PubMed ID: 16685447
[TBL] [Abstract][Full Text] [Related]
8. uPA is upregulated by high dose celecoxib in women at increased risk of developing breast cancer.
Qin W; Zhu W; Hewett JE; Rottinghaus G; Chen YC; Flynn JT; Kliethermes B; Mannello F; Sauter ER
BMC Cancer; 2008 Oct; 8():298. PubMed ID: 18922176
[TBL] [Abstract][Full Text] [Related]
9. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.
Castelló R; Landete JM; España F; Vázquez C; Fuster C; Almenar SM; Ramón LA; Radtke KP; Estellés A
Thromb Res; 2007; 120(5):753-62. PubMed ID: 17258797
[TBL] [Abstract][Full Text] [Related]
10. Celecoxib, a cyclooxygenase-2 inhibitor, induces apoptosis in human osteosarcoma cell line MG-63 via down-regulation of PI3K/Akt.
Liu B; Shi ZL; Feng J; Tao HM
Cell Biol Int; 2008 May; 32(5):494-501. PubMed ID: 18078766
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer.
Li XF; Yan PJ; Shao ZM
Oncogene; 2009 Nov; 28(44):3937-48. PubMed ID: 19701247
[TBL] [Abstract][Full Text] [Related]
12. [Celecoxib promotes apoptosis of breast cancer cell line MDA-MB-231 through down-regulation of the NF-kappaB pathway].
Wang L; Liu LH; Shan BE; Zhang C; Sang MX; Li J
Ai Zheng; 2009 Jun; 28(6):569-74. PubMed ID: 19635192
[TBL] [Abstract][Full Text] [Related]
13. Synergistic tumoricidal effect between celecoxib and adenoviral-mediated delivery of mda-7 in human breast cancer cells.
Suh YJ; Chada S; McKenzie T; Liu Y; Swisher SG; Lucci A; Hunt KK
Surgery; 2005 Sep; 138(3):422-30. PubMed ID: 16213894
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of human breast cancer cell invasion by siRNA against urokinase-type plasminogen activator.
Huang HY; Jiang ZF; Li QX; Liu JY; Wang T; Zhang R; Zhao J; Xu YM; Bao W; Zhang Y; Jia LT; Yang AG
Cancer Invest; 2010 Aug; 28(7):689-97. PubMed ID: 20636107
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
[TBL] [Abstract][Full Text] [Related]
16. TNF alpha acting on TNFR1 promotes breast cancer growth via p42/P44 MAPK, JNK, Akt and NF-kappa B-dependent pathways.
Rivas MA; Carnevale RP; Proietti CJ; Rosemblit C; Beguelin W; Salatino M; Charreau EH; Frahm I; Sapia S; Brouckaert P; Elizalde PV; Schillaci R
Exp Cell Res; 2008 Feb; 314(3):509-29. PubMed ID: 18061162
[TBL] [Abstract][Full Text] [Related]
17. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
Xue A; Xue M; Jackson C; Smith RC
Int J Biochem Cell Biol; 2009; 41(8-9):1731-8. PubMed ID: 19433314
[TBL] [Abstract][Full Text] [Related]
18. Intrinsic focal adhesion kinase activity controls orthotopic breast carcinoma metastasis via the regulation of urokinase plasminogen activator expression in a syngeneic tumor model.
Mitra SK; Lim ST; Chi A; Schlaepfer DD
Oncogene; 2006 Jul; 25(32):4429-40. PubMed ID: 16547501
[TBL] [Abstract][Full Text] [Related]
19. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors.
Gutova M; Najbauer J; Frank RT; Kendall SE; Gevorgyan A; Metz MZ; Guevorkian M; Edmiston M; Zhao D; Glackin CA; Kim SU; Aboody KS
Stem Cells; 2008 Jun; 26(6):1406-13. PubMed ID: 18403751
[TBL] [Abstract][Full Text] [Related]
20. Cyclooxygenase-2 uses the protein kinase C/ interleukin-8/urokinase-type plasminogen activator pathway to increase the invasiveness of breast cancer cells.
Simeone AM; Nieves-Alicea R; McMurtry VC; Colella S; Krahe R; Tari AM
Int J Oncol; 2007 Apr; 30(4):785-92. PubMed ID: 17332916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
